The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
Open accessAbstract
BACKGROUND: Influenza A (H5N1) viruses could cause a severe worldwide epidemic, with high attack rates, large numbers of deaths and hospitalizations, and wide disruption. Effective vaccines against these viruses in humans are urgently needed. METHODS: We conducted a multicenter, double-blind two-stage study involving 451 healthy adults 18 to 64 years of age who were randomly assigned in a 2:2:2:2:1 ratio to receive two intramuscular doses of a subvirion influenza A (H5N1) vaccine of 90, 45, 15, or 7.5 microg of hemagglutinin antigen or placebo. The subjects were followed for the safety analysis for 56 days. Serum samples obtained before each vaccination and again 28 days after the second vaccination were tested for H5 antibody by microneutralization and hemagglutination inhibition. RESULTS: Mild pain at the injection site was the most common adverse event for all doses of vaccine. The frequency of a serum antibody response was highest among subjects receiving doses of 45 microg or 90 microg. Among those who received two doses of 90 microg, neutralization antibody titers reached 1:40 or greater in 54 percent, and hemagglutination-inhibition titers reached 1:40 or greater in 58 percent. Neutralization titers of 1:40 or greater were seen in 43 percent, 22 percent, and 9 percent of the subjects receiving two doses of 45, 15, and 7.5 microg, respectively. No responses were seen in placebo recipients. CONCLUSIONS: A two-dose regimen of 90 mug of subvirion influenza A (H5N1) vaccine does not cause severe side effects and, in the majority of recipients, generates neutralizing antibody responses typically associated with protection against influenza. A conventional subvirion H5 influenza vaccine may be effective in preventing influenza A (H5N1) disease in humans. (ClinicalTrials.gov number, NCT00115986.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia
Li, K. S., Guan, Y., Wang, J., Smith, G. J. D., Xu, K. M., Duan, L., Rahardjo, A. P., Puthavathana, P., Buranathai, C., Nguyen, T. D., et al. (2004) · Nature · doi:10.1038/nature02746 · Cited by 1,343
Generation of influenza A viruses entirely from cloned cDNAs
Neumann, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Gao, P., Hughes, M., Perez, D. R., Donis, R., Hoffmann, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9345 · Cited by 1,278
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J. D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa054512 · Cited by 901
Probable Person-to-Person Transmission of Avian Influenza A (H5N1)
Ungchusak, K., Auewarakul, P., Dowell, S. F., Kitphati, R., Auwanit, W., Puthavathana, P., Uiprasertkul, M., Boonnak, K., Pittayawonganon, C., Cox, N. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044021 · Cited by 869
Avian Influenza A (H5N1) in 10 Patients in Vietnam
Hien, T. T., Liem, N. T., Dung, N. T., San, L. T., Mai, P. P., Chau, N. V. V., Suu, P. T., Dong, V. C., Mai, L. T. Q., Thi, N. T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040419 · Cited by 839
Rowe, T., Abernathy, R. A., Hu-Primmer, J., Thompson, W. W., Lu, X., Lim, W., Fukuda, K., Cox, N. J., & Katz, J. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.937-943.1999 · Cited by 811
Self-citationNicholson, K. G., Colegate, A. E., Podda, A., Stephenson, I., Wood, J., Ypma, E., & Zambon, M. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05066-2 · Cited by 440
Dose Sparing with Intradermal Injection of Influenza Vaccine
Kenney, R. T., Frech, S. A., Muenz, L. R., Villar, C. P., & Glenn, G. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa043540 · Cited by 422
Serum Antibody Responses after Intradermal Vaccination against Influenza
Belshe, R. B., Newman, F. K., Cannon, J., Duane, C., Treanor, J., Van Hoecke, C., Howe, B. J., & Dubin, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa043555 · Cited by 332
Self-citationSafety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans
Treanor, J. J., Wilkinson, B. E., Masseoud, F., Hu-Primmer, J., Battaglia, R., O'Brien, D., Wolff, M., Rabinovich, G., Blackwelder, W., & Katz, J. M. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00395-9 · Cited by 323
Self-citation
Cited by
Imai, M., Watanabe, T., Hatta, M., Das, S. C., Ozawa, M., Shinya, K., Zhong, G., Hanson, A., Katsura, H., Watanabe, S., et al. (2012) · Nature · doi:10.1038/nature10831 · Cited by 1,523
Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00110-09 · Cited by 594
Henry Dunand, C. J., Leon, P. E., Huang, M., Choi, A., Chromikova, V., Ho, I. Y., Tan, G. S., Cruz, J., Hirsh, A., Zheng, N.-Y., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.014 · Cited by 268
Self-citationGalli, G., Hancock, K., Hoschler, K., DeVos, J., Praus, M., Bardelli, M., Malzone, C., Castellino, F., Gentile, C., McNally, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903181106 · Cited by 263
Scientific barriers to developing vaccines against avian influenza viruses
Subbarao, K., & Joseph, T. (2007) · Nature Reviews Immunology · doi:10.1038/nri2054 · Cited by 255
Metadata
- Authors
- Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-30
- Volume
- 354
- Issue
- 13
- Pages
- 1343-1351
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2131170401
- Cited by
- 698
- References
- 16
- FWCI
- 69.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine. https://app.cochat.ai/papers/10.1056/nejmoa055778
- The paper
- Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M. (2006). Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine. New England Journal of Medicine. https://doi.org/10.1056/nejmoa055778
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
